Trial Profile
A randomized, double-blind Phase 3 study of S-474474 in patients with essential hypertension, - Evaluation in non-responder to irbesartan -
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 25 May 2016
Price :
$35
*
At a glance
- Drugs Irbesartan/trichlormethiazide (Primary)
- Indications Essential hypertension
- Focus Registrational; Therapeutic Use
- Sponsors Shionogi
- 25 May 2016 New trial record